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Abstract
Background: The ProteomeLab™ PF 2D platform is a relatively new approach to global protein
profiling. Herein, it was used for investigation of plasma proteome changes in amyotrophic lateral
sclerosis (ALS) patients before and during immunization with glatiramer acetate (GA) in a clinical
trial.
Results: The experimental design included immunoaffinity depletion of 12 most abundant proteins
from plasma samples with the ProteomeLab™ IgY-12 LC10 column kit as first dimension
separation, also referred to as immuno-partitioning. Second and third dimension separations of the
enriched proteome were performed on the PF 2D platform utilizing 2D isoelectric focusing and
RP-HPLC with the resulting fractions collected for analysis. 1D gel electrophoresis was added as a
fourth dimension when sufficient protein was available. Protein identification from collected
fractions was performed using nano-LC-MS/MS approach. Analysis of differences in the resulting
two-dimensional maps of fractions obtained from the PF 2D and the ability to identify proteins from
these fractions allowed sensitivity threshold measurements. Masked proteins in the PF 2D fractions
are discussed.
Conclusion: We offer some insight into the strengths and limitations of this emerging proteomic
platform.
Background
Despite technological advances in proteomics, analysis of
complex biological samples remains a significant chal-
lenge [1]. Some of the most complex biological samples
routinely submitted for proteomic profiling include
serum or plasma [2-4]. While disease markers abound in
plasma are reflective of ongoing disease, complexity of
sample due to post-translational modifications (PTMs)
and protein isoforms presents major obstacles for biomar-
ker identification [5-8]. Reproducibility, sensitivity, reso-
Published: 12 September 2008
Proteome Science 2008, 6:26 doi:10.1186/1477-5956-6-26
Received: 1 April 2008
Accepted: 12 September 2008
This article is available from: http://www.proteomesci.com/content/6/1/26
© 2008 Schlautman et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Proteome Science 2008, 6:26 http://www.proteomesci.com/content/6/1/26
Page 2 of 12
(page number not for citation purposes)
lution, and high throughput analysis are among the
developing areas for proteomic platforms [9]. The need
for better separation and analytical techniques cannot be
overstated [10].
Improvements in proteomics platforms have been real-
ized in recent years [11,12]. For example, 2D SDS-PAGE
when combined with difference in gel electrophoresis
(DIGE) was developed as a profiling platform wherein
proteins are identified based on electrospray ionization
mass spectrometry (ESI-MS/MS) of trypsin-derived pep-
tides. However, resolution of hydrophobic proteins and
those within a high molecular mass range is limited [13-
15]. This may be overcome using a combination of molec-
ular sieving chromatography with the multi-dimensional
protein identification technology (MudPIT) or protein
microarrays [16]. Other "bottom-up" tools, such as sur-
face enhanced laser desorption ionization-time of flight
(SELDI-TOF) and matrix-assisted labelled desorption/
ionization-time of flight (MALDI-TOF), while useful, do
not address PTMs in complex body fluids. Another critical
need is protein quantification since changes in proteome
profiles may be subtle, yet biologically significant [12].
For example, protein glycosylation or phosphorylation
leading to functional modification affects only a small
percentage of the total protein pool linked to physiologi-
cal changes. Therefore, fractionating complex protein
mixtures while maintaining intact proteins in liquid
phase is a most desirable feature for use in further analyses
("top-down proteomics"). Fractions collected in liquid
phase would provide simpler and more informative sec-
ondary analysis, in contrast to gel-embedded proteins in
2D DIGE [17-19] where intact protein recovery is difficult
and associated with greater quantitative loss. Addition-
ally, once protein is enzymatically digested for LC-MS/MS
analysis, it cannot be used for other analysis such as West-
ern blot assays.
ProteomeLab™ PF 2D offers an alternative approach to
protein profiling that addresses issues of complexity and
utilization of fractions after analysis. To assess the utility
of the PF 2D platform for proteomic profiling, we com-
pared plasma samples recovered from amyotrophic lateral
sclerosis (ALS) patients who were immunized with glati-
ramer acetate (GA) to those from non-immunized ALS
patients. Strengths and weaknesses of this new proteomic
platform for biomarker discovery are discussed.
Results
Plasma sample immunodepletion
Patient serum/plasma represents clinical material that is
easily obtained with fewer restrictions compared to other
sample types, including cerebrospinal fluid or tissue
biopsy; thus, it is one of the most commonly tested
patient material from which diagnostic tests are per-
formed. Collectively, protein concentrations span a very
broad range (1012-fold) [20] in serum/plasma from which
the differential concentration in individual protein con-
centrations presents potential targets for the discovery of
clinically important biomarkers. However, the presence of
very highly abundant proteins and the complexity of
plasma proteins present formidable challenges. Twelve of
the most abundant proteins comprise ~96% of the total
protein mass from human plasma, with albumin com-
prising approximately 40–50% of protein. Presence of
these abundant proteins in plasma samples masks differ-
ential levels of low to medium abundant ones. One strat-
egy is to remove the most abundant proteins prior to
profiling. To assess that approach, we used immunoaffin-
ity chromatography with a column that is based on IgY
technology to selectively remove 12 of the most abundant
proteins in human serum/plasma (Figure 1, experimental
Experimental designFigu e 1
Experimental design. Experimental design of multidimen-
sional fractionation using plasma from ALS patients involved 
in a phase II clinical trial with GA.
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design). One caveat of immunodepletion is that potential
biomarkers that bind to albumin or highly abundant pro-
teins may also be completely or partially depleted from
serum samples through protein-protein interactions.
However, this possibility can be evaluated with further
analyses upon elution of the adherent protein fraction.
Although the IgY-12 LC10 affinity column has the highest
capacity of commercial immunoaffinity products cur-
rently available, only 250 μL of plasma sample can be
processed during one chromatographic cycle. Flow
through fractions (8–27 minutes) containing unbound
proteins (Figure 2) were collected, pooled, concentrated,
and submitted for analysis on the PF 2D platform. Protein
yields from the flow through fractions were between 0.73
and 3.0 mg per mL of plasma.
Protein fractionation 2-dimensions (PF 2D)
The proteomic profiling platform ProteomeLab™ PF 2D
offers 2-dimensional fractionation in which intact pro-
teins are first separated by chromatofocusing proteins by
pI and separated in the second dimension by their hydro-
phobic properties. The pH profiles from the chromatofo-
cusing absorbencies were obtained from first dimension
separation at 280 nm and thirty fractions were selected
from each sample to submit for second dimension separa-
tion by hydrophobic chromatography. Second dimension
absorbance profiles were compiled and displayed as a
two-dimensional map using a feature of Mapping Tools
software. The map displays pI fractions as lanes with the
colour intensity of each band (absorbance at 214 nm) cor-
responding to protein bands located at their retention
time of the second dimension separation (Figure 3A and
3B, Table 1).
Challenges associated with peak alignment are similar to
those found during the alignment of spots in the analysis
of 2-dimensional gel electrophoresis. Comparison of two
separate UV/pI maps consisting of the entire pH gradient
was afforded by a module (DeltaVue) of the Mapping
Tools data processing software. A second module (Multi-
Vue) enables the analysis of a selected pH lane from mul-
tiple sample runs. In both methods, proper peak
alignment between samples provides a critical analytical
function. Using the Paired Peak function of MultiVue in
Mapping Tools, second dimension chromatograms were
aligned by setting the paired peak value at +/- 0.5% to ini-
tially determine if peaks should be paired. After confirma-
tion of automatic pairing, minor manual adjustments of
retention times (RT) were made to accommodate align-
ment protocols. For example, raw data from one analyzed
ImmunodepletionFigure 2
Immunodepletion. Chromatography of immunodepletion of plasma using ProteomeLab™ IgY-12. 250 μL of human plasma 
was partitioned with LC 10 column at an absorbance of 280 nm. The Flow Through was collected (8–27 min) and used for fur-
ther analysis with PF 2D. The bound fraction was not analyzed.
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Results of profiling analysisFig re 3
Results of profiling analysis. A. PF 2D two-dimensional heat maps of a representative set of samples obtained from one 
individual before and after GA immunization. PF 2D first dimension separation is based on isoelectric point (pI). PF 2D second 
dimension separation utilizes reverse phase HPLC fractionation. B. Comparison of two aligned peaks from analyses shown in 
(A) displaying a quantitative difference in protein contents measured by peak area (volume). Colour scheme ranges from purple 
(low absorbance) to red (high absorbance). The difference between absorbencies is shown in the middle as either a red or 
green band, representing the sample with greater absorbance at a specific peak.
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peak (fraction corresponding to pH 5.89-5.59 and RT
16.04–16.71) yielded a raw range of 8.4 seconds in RT
throughout six samples. However, following alignment
adjustments, the range was within 4.2 seconds, providing
greater assurance when selecting peaks for quantitative
and qualitative analysis.
Our data indicate that alignment and comparisons of the
first dimension separation profiles were consistent. Align-
ment in second dimension, RP-HPLC, was also precise as
differences in retention times between samples were in a
range of less than 15 seconds. Figure 4 shows an example
in which differences in retention times are less than 6 sec
(0.1 min). Although automatic alignment is a standard
software feature utilized in these studies for course align-
ment, manual alignment has proven necessary to refine
peak analysis. Protein identification by LC-MS/MS pre-
sented in Table 2 afforded a level of confidence in our
(manual) method of alignment. Nevertheless, alignment,
whether automatic or manual, should be used with cau-
tion and peak identification must be validated.
When comparing corresponding fractions from different
samples, differences in retention times become critical for
peak resolution since fraction collection intervals are
determined prior to profile analysis. Therefore, a differ-
ence of several seconds may result in one peak being split
into two fractions in one sample while collected entirely
in one fraction for another. This is an inherent issue with
LC based separation, whether stand-alone or in combina-
tion with other modes of separation. Thus, methods of
separation and collection must be considered at the time
when parameters are first set. One of several approaches
to analyzing divided peaks involves determining the pro-
tein composition of each fraction. Another approach is to
pool both adjacent fractions to increase the chances of
protein identification from the corresponding split peak.
However, pooling fractions may create more complexity
in the sample and affect further analysis, such as increas-
ing the number of proteins identified within the pool.
Protein identification
High confidence protein identification is an essential step
in most proteomic studies. The ProteomeLab™ PF 2D,
unlike 2D DIGE, offers the added advantage that collected
fractions are in liquid phase and can be utilized directly
for any of various analytical procedures, such as mass
spectrometer analysis, enzymatic digests, additional frac-
tionation, Western blot, or a combination of analytical
tests. Additionally, more material can be fractionated
Table 1: Summary of fractions selected for mass spectrometry analyses.
Fraction ID**
(Fraction Coordinates)
Patient 1 Patient 2 Patient 3
GA Immunization
Before
(B)
After
(A)
Before
(B)
After
(A)
Before
(B)
After
(A)
F1
(pH: 5.90-5.60, RT:16.04–16.71)
1.49* 1.11 1.76 1.49 1.41 1.46
F2
(pH: 7.10-6.80, RT:14.03–14.70)
0.004 0.006 0.023 0.009 0.008 0.009
F3
(pH: 6.20-5.90, RT:14.70–15.37)
0.043 0.049 0.06 0.049 0.03 0.031
F4
(pH: 6.50-6.20, RT:16.04–16.71)
0.28 0.343 0.57 0.533 0.23 0.11
F5
(pH: 5.90-5.60, RT:16.71–17.38)
0.178 0.171 0.507 0.24 0.134 0.133
F6
(pH: 6.20-5.90, RT:15.37–16.04)
0.01 0.02 0.1 0.09 0.06 0.03
F7
(pH: 4.99-4.88, RT:14.70–15.37)
0.24 0.49 0.48 0.805 0.51 0.46
F8
(pH: 6.80-6.50, RT:15.37–16.04)
0.002 0.016 0.054 0.04 0.01 0.005
F9
(pH: 6.80-6.50, RT:16.04–16.71)
0.11 0.03 0.045 0.065 0.02 0.01
F10
(pH: 6.80-6.50, RT:14.03–14.70)
0.005 0.006 0.024 0.010 0.0086 0.009
Second dimension fractions representing selected pH ranges and retention times (RT). Corresponding peak heights are listed as absorbance units at 
214 nm (*). Although there may be several peaks/fraction, values represent the peak having the greatest absorbance in the corresponding fraction. 
Fraction IDs are used in Table 2 (**).
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using 2D LC (up to 5 mg with the PF 2D) than with gel
electrophoresis, thus significantly increasing the sensitiv-
ity of protein identification.
In the first step of this study, we investigated the correla-
tion between detection of individual plasma fractions by
UV absorbance and our ability to identify proteins with
high confidence (two or more peptides). We digested pro-
teins in a given plasma sample with trypsin and analyzed
the digest for resulting peptides using nano-LC-MS/MS
sequencing. Table 1 summarizes fractions with analogous
pH, retention time, and similar peak height absorbance
chromatograms. Selected fractions were digested and ana-
lyzed by nano-LC-MS/MS. Fractions with a peak height
greater than 0.100 absorbance units at 214 nm provided
enough material to identify proteins with high confidence
using our instrumentation. Proteins in fractions with peak
height below 0.050 were either identified with low confi-
dence or remained unidentified. Proteins in fractions
within the intermediate peak height range of 0.05 and
0.10 appeared to be the lower limit of identification by
nano-LC-MS/MS. Table 2 displays only the proteins iden-
tified with high confidence from examined fractions.
Using both automatic and manual alignment protocols,
the same proteins were identified among several fractions
across all six analyzed samples. These results indicated
that using automatic alignment with minor manual
adjustments provides enough confidence to pool corre-
sponding sample fractions with low protein content and
use them for high confidence protein identification with-
out risk of mixing neighbouring peaks. The capacity to
provide peak pooling enhances the utility of this pro-
teomic platform.
Fourth dimension fractionation
One of the advantages of the PF 2D profiling platform is
a possibility of fractionation in the fourth dimension. In
our experimental design, IgY immunodepletion (parti-
tioning) served as first dimension partitioning, isoelectric
focusing provided second dimension analysis, and RP-
HPLC yielded the third dimension. Several fractions after
3 dimensional analyses were selected for a fourth dimen-
sion, 1-dimensional electrophoresis (1DE), to evaluate
whether the fraction isolated as a single peak consisted of
only one protein. Frequently, fractions (covering a reten-
tion time of 0.67 min) with high peak height contain sev-
eral proteins whose quantities are opposite to each other,
thus masking differential expression. We selected one
matching fraction from all six samples (pH 5.9 to 5.6,
retention time 16.04 to 16.71 min.) with peak height
ranging between 1.11 and 1.76 (Table 1). Analysis of
these six matching fractions based on levels of absorbance
after 3-dimensional fractionation did not demonstrate
statistical differences between fractions, thus indicating
RP-HPLCFigure 4
RP-HPLC. Differences in retention times (RT) (second dimension) displayed as bands for a specific peak detected and aligned 
in 6 samples using MultiVue software. The displayed peak corresponds to Patient 3 before treatment and has a RT of 16.62 
min. Range of retention times was less than 6 sec.
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that the total amount of protein in each fraction was the
same. We expected and further confirmed by 1 DE that
these fractions consisted of multiple, non-separated, pro-
teins. Therefore, in a subsequent step, we analyzed by 1
DE equal amounts of each fraction containing equal
amounts of protein based on absorbance at 214 nm. As
expected, this analysis showed multiple bands in each
fraction (Figure 5). A characteristic pattern showed
increased intensity of a protein band with a molecular
mass above 62 kDa in samples from immunized patients.
It is possible that using narrower pH fractionation, e.g. 0.1
units instead of 0.3 units used in this study, would help to
further separate proteins. This band was identified as
hemopexin based on nano-LC-MS/MS analysis of pep-
tides derived from tryptic digests and demonstrates that
levels of this protein are increased in patients immunized
with GA. The most extensively studied function of hemo-
pexin is its binding heme, having the highest affinity of
any known protein. Also, as a heme scavenger, hemo-
pexin protects organisms from the oxidative damage that
can be caused by free heme. Interestingly, histidine-rich
glycoprotein precursor, whose function is not understood
and which has been found in this study, is also a heme
binding protein. Both proteins are made by liver and
secreted to plasma.
Molecular mechanism(s) underlying ALS remain enig-
matic and no curative or ameliorative therapy exists for
this disorder that leads to degeneration of upper and
lower motor neurons and ultimate death. Because ALS
appears to be multifactoral, involving interactions among
microglia, astrocytes, neurons, and muscles, one can
anticipate that efficacious therapy would require a
number of therapeutic approaches involving adjunct
Table 2: Summary of results from mass spectrometry analyses.
Protein No Protein Fraction ID: Patient Sample MW NCBI Accession # pI
1 Hemopexin F1: 1A,2A,3B,3A
F8: 1B,1A,2B,2A,3B
F6: 1B,1A,2B,2A,3B,3A
F5: 1B,1A,2B,2A,3B,3A
F7: 1B,1A,2B,3B
51676 11321561 6.55
2 Plasminogen F1: 1A,2A,3B,3A
F4: 1A,2A,3B,3A
F6: 2a
90569 4505881 7.04
3 Anti-thrombin F1: 2A,3B 13788 23978644 5.91
4 Histidine-rich glycoprotein precursor F1: 1B,1A,3B
F4: 1B,1A,2B,2A,3B,3A
F9: 2B
59578 4504489 7.09
5 Complement Factor I F5: 1A,2B,2° 65720 119392081 7.72
6 Complex of the Catalytic Domain of Human Plasmin and 
Streptokinase
F1: 1A,2A,3B
F4: 1A,2B,2A,3B,3A
F9: 2B
27286 5821850 8.27
7 Prealbumin F1: 2A
F5: 1B,2B,2A,3B
15919 219978 5.52
8 A Chain A, prealbumin F1: 2A
F8: 1B
F5: 1B,2B,2A,3B
13760 230651 5.55
9 Beta-2 glycoprotein I apolipoprotein H F1: 1A,3B
F4: 1A,2A
F6: 1A,2B,2A,3B
38312 28810 8.34
10 Gelsolin isoform a precursor F1: 3B
F9: 2B
F6: 2B
F5: 1B,3B,3A
85697 4504165 5.90
11 Kringle 2 Domain of Human Plasminogen F4: 1A,2A,3B 9637 6573460 7.55
12 Complement factor H-related protein 1 precursor 
(FHR-1)
F6: 1A,2B,2A,3B
F7: 2A
37661 543981 7.75
13 H factor (complement)-like 3 F6: 2A 30651 5031695 6.00
14 Retinol-binding protein 4, plasma precursor F1: 2B
F5: 2B
23010 55743122 5.76
15 Coagulation factor XII-Mie F5: 2A 67735 24899162 8.03
16 Glutathione peroxidase 3 precursor F5: 2A 25505 121672 8.20
17 Factor H F7: 2A 139125 31965 6.28
Identification by LCMS/MS of proteins in plasma from three ALS patients before (B) and after (A) GA immunization. Only proteins with two or 
greater sequenced peptides are listed. Coordinates for Fraction IDs are listed in Table 1.
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modalities that target several pathways associated with
microglia activation and motor neuron degeneration.
One immunomodulatory strategy using a synthetic poly-
meric immunogen, GA, which cross-reacts with CNS pro-
tein epitopes and is currently clinically utilized in the
treatment of relapsing/remitting multiple sclerosis, targets
several of these pathways [21]. In a recent phase II clinical
trial, GA treatment of ALS patients proved to be safe and
well tolerated [22]. Whereas significant diminution of
lymphocyte proliferation was observed, subsequent stud-
ies showed increased concentration of anti-GA antibodies
in plasma from treated patients [23]. To fully evaluate
plasma differences in immunized patients compared to
pre-immunized ALS patients and probe putative treat-
ment targets for ALS, we employed a strategy of protein
fractionation that allowed the separation of plasma pro-
teins into several hundred fractions that are amenable to
downstream evaluation.
Discussion
ProteomeLab™ PF 2D is a new technology platform in
proteomics [17-19,24-26] and literature reports using this
platform have continued to emerge, totaling more than
40 to date. Our first approach discovered fewer differences
than originally expected. However, the capacity for fourth
dimensional separation and additional analysis provided
an opportunity to further investigate selected fractions
that otherwise would not have been available using the
typical "bottom-up", non-recoverable tandem methods of
separation and analysis used in conventional proteomics.
This was possible because intact proteins were initially
separated, analyzed and recovered in liquid phase. We
were also able to identify isogenous fractions to pool
when individual fractions contained insufficient amounts
of protein for identification, a feature made possible by
the ability to reproduce inter-sample fractionation pat-
terns and precisely align peaks among replicate samples.
Another strength of this platform is the flexibility to
choose the number of fractions acquired per sample. We
selected 30 first dimension fractions for second dimen-
sion separation, resulting in fractions covering a wide pH
range and producing over 700 fractions per sample. How-
ever, the number of analyzed fractions and method
parameters are within the investigator's prerogative. First,
the collection of fractions based on the pH gradient can be
adjusted to increase or decrease fractions collected; this is
especially beneficial when the proteins of interest occur in
a narrow pH range. Second, larger pH intervals for frac-
tion collection may result in a higher number of proteins
contained within each fraction, diminishing the separa-
tion of proteins and the potential for biomarker discovery.
Narrowing pH intervals increases resolution, but will also
increase the number of fractions to be analyzed in the sec-
ond dimension, taking more time and further decreasing
throughput. Similarly, the number of first dimension frac-
tions to be run in the second dimension can be selected.
Also, slower gradient elution from RP-HPLC columns can
be utilized but will result in longer second dimension
runs and requires some initial experimentation to opti-
mize the desired analysis. Adjusting pH parameters and
acetonitrile gradients may be useful, but needs to be
applied with caution to assure the overall benefit from
profiling.
We have yet to analyze fractions in great depth for PTM
differences, although such modifications can be indicative
of changes resulting from immunization. In particular,
shifts in protein isoelectric point usually indicate changes
resulting from PTMs [27]. Therefore, it is possible that the
identification of similar proteins from a variety of pH and
RT fractions results from PTMs and/or protein fragmenta-
tion, as was seen in our study. Other approaches of sam-
ple fractionation prior to profiling can be included. For
example, use of "Equalizer® beads" [28-30] might be an
1D ElectrophoresisFigure 5
1D Electrophoresis. 1D electrophoresis (fourth dimension fractionation) showing differential expression of protein band 
above 62 kDa m.w. marker. Hemopexin was identified as the most prominent protein in this band by LCMS/MS sequencing. 
Equal amount of protein (based on absorbance at 214 nm) from each sample was loaded per lane. Gel was stained with 
SyproRuby.
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advantageous alternative or addition to broadly used
immunodepletion of the most abundant proteins. Using
lectin columns for isolation of subsets of post-translation-
ally glycosylated proteins offers another approach to
address challenges of profiling and discovery of biomark-
ers in a very complex mixture of proteins, especially when
changes are subtle [31,32]. Still, given the sample recovery
capacity and sample concentration, those studies are
within the realm of this platform.
Conclusion
In summary, we found the ProteomeLab™ PF 2D to be a
useful automated proteomic profiling platform. There are
several strengths of this approach. One advantage over the
second dimension of 2-dimensional electrophoresis (2-
DE) is the separation of proteins, which might be very
similar in size but quite different in their biochemical
characteristics due to post-translational modification.
Also, this platform can be used for profiling basic and
hydrophobic proteins that are hard to analyze by 2-DE
[33,34]. Another advantage is that fractionated proteins
are maintained in a liquid phase, making them available
for various assays without loss of material (e.g., extraction
from polyacrylamide gel) and/or allowing fractionation
by other means. Moreover, due to the automated nature
of this platform, the option of using only chromatofocus-
ing for separation affords an attractive advantage over
conventional gel-based separation by isoelectric focusing.
Weaknesses of the ProteomeLab™ platform include low
throughput, allowing 2–3 samples per week per instru-
ment, and relatively large amount of sample required for
analysis. Although multiple instruments can be run in
parallel to increase throughput, this is very expensive.
Large amount of sample is not an issue when serum/
plasma samples are analyzed. However, other clinical
material such as tissue biopsies might not be available in
sufficient amounts. Also, the masking of differential pro-
tein expression among samples by opposite quantities of
protein in a given fraction may present a problem when
looking for potential biomarkers, as seen by the differen-
tial expression of hemopexin in our study. We have pre-
sented preliminary data regarding the effects of GA
treatment for ALS and have found the ProteomeLab™ PF
2D to be a promising platform for protein profiling and a
means for biomarker discovery.
Methods
Samples
Peripheral blood samples from ALS patients used in this
study were obtained from Columbia University, New
York. ALS patients were treated daily with 20 mg of GA
over a six month period [22]. Samples were collected in
acid citrate dextrose tubes and after centrifugation at 800
× g for 10 min, the plasma was harvested, distributed into
1 mL aliquots, and stored at -80°C. Plasma from 3 ALS
patients (collected prior to treatment and 2, 4, and 5
months after initiation of GA treatment) was used in this
investigation.
Sample delipidation
Plasma samples were centrifuged at 18000 × g, 15 min at
4°C. The middle layer was collected and diluted 1:2.5
(0.25 mL plasma + 0.375 mL) in dilution buffer (10 mM
Tris-HCl, pH 7.4, 0.15 M NaCl). Next, particles and aggre-
gates were removed from samples by filtration through a
0.45 μm spin filter at 9200 × g for 1 min.
Immunodepletion (partitioning)
To remove 12 highly abundant proteins, we utilized the
ProteomeLab™ IgY-12 High Capacity Proteome Partition-
ing Kit (Beckman Coulter, Fullerton, CA) according to
manufacturer's recommendations. The kit included a
LC10 affinity column (12.7 × 79.0 mm) with a capacity of
0.25 mL human plasma per cycle and optimized buffers
for sample preparation, loading, washing, and eluting.
The LC10 column contains affinity-purified chicken IgY
antibodies directed against serum albumin, fibrinogen,
IgG, transferin, IgA, IgM, apoA-I, apoA-II, haptoglobin,
α1-antitrypsin, α2-macroglobulin, and α1-acid glycopro-
tein, which are covalently conjugated to polymeric
microbeads. After the enriched flow through fractions
containing low to medium abundant proteins were col-
lected, the bound and highly abundant proteins were
eluted with stripping buffer (0.1 M Glycine-HCl, pH 2.5).
The column was then neutralized with 0.1 M Tris-HCl, pH
8.0 buffer. Finally, the column was re-equilibrated with
dilution buffer at a flow rate of 2 mL/min. Collected
bound fractions were neutralized with 0.1 M Tris-HCl.
Flow through and eluted fractions were stored at -80°C
until further analysis.
Sample preparation for PF 2D first dimension (isoelectric 
focusing)
Collected flow through fractions were thawed at room
temperature and concentrated down to 0.50 mL using an
Amicon Ultra-15 centrifugal filter (Millipore, Billerica,
MA) previously washed with 3 mL of ProteomeLab™ Start
Buffer (Beckman Coulter, pH 8.5). Next, 2 mL of plasma
denaturing buffer (7.5 M urea, 2.5 M thiourea, 12.5%
glycerol, 62.5 mM Tris-HCl, 2.5% (w/v) n-octylglucoside,
1.25 mM EDTA) was added to the concentrator and left at
room temperature for 30 min while shaking. Samples
were removed and centrifuged using two 1.5 mL screw-
cap microcentrifuge tubes at 15,000 × g for 1 hr at 18°C.
PD-10 Desalting Columns (GE Healthcare) were prepared
by equilibration with 25 mL of Start Buffer. Sample was
removed from the plasma denaturing buffer and placed
into Start Buffer by placing sample load (2.5 mL) onto
PD-10 column, discarding effluent, and collecting the
desalted sample with 3.5 mL of Start Buffer. Resulting
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sample was filtered through a 0.45 μm spin filter previ-
ously washed with the Start Buffer. Protein concentration
was determined by the Micro BCA Assay Kit (Pierce Bio-
technology, Rockford, IL).
Profiling
Protein profiling using ProteomeLab™ PF 2D system con-
sists of two steps: first dimension fractionation is chro-
matofocusing and second dimension is reverse phase
HPLC fractionation. The 32 Karat™ Software (Beckman
Coulter) was used for data processing and calculation of
peak areas and heights.
First dimension fractionation
The first dimension was performed at room temperature
with a flow rate of 0.2 mL/min using the HPCF column
Start Buffer (pH 8.5), Eluent Buffer (pH 4.0), High Ionic
Strength Wash + (1 M NaCl in 30% Isopropanol), and
water. It was performed at room temperature with a flow
rate of 0.2 mL/min. After equilibration with the Start
Buffer for 130 min, the samples (1–5 mg of protein) were
injected onto the chromatofocusing column and proteins
separated based on isoelectric point (pI). Thirty-five min
after injection, Eluent Buffer was initiated to generate a
pH gradient (8.5–4.0). Shortly after the gradient reached
pH 4.0, the column was washed with HISS+ (135–175
min after injection) to remove hydrophobic proteins and
proteins with a pI under 4.0. Finally, the column was
washed with water for 45 minutes (175–220 min after
injection). Proteins were detected by absorbance at 280
nm by a UV detector. Based on the pH gradient generated,
fractions were collected with the fraction collector/injec-
tor module (FC/I) at 0.3 pH intervals during pH gradient
elutriation (8.3–4.0), otherwise fractions were collected
every 8.5 min.
Second dimension fractionation
The second dimension separations were performed with
an RP-HPLC column and two solvents, 0.1% trifluoroace-
tic acid (TFA) in HPLC water (Solvent A) and 0.08% TFA
in acetonitrile (ACN) (Solvent B). Separation was exe-
cuted at 50°C at a flow rate of 0.75 mL/min and protein
containing fractions detected by UV absorbance at 214
nm. Equilibration was achieved with Solvent A for 10
minutes followed by Solvent B for 5 minutes prior to each
injection. From selected first dimension fractions, 0.250
mL were injected, run for two minutes, and the column
eluted with a linear gradient of 0–100% Solvent B for 30
min. (3.33% change in B solvent/min). Next, Solvent B
was continued for four minutes, followed by re-equilibra-
tion with 100% Solvent A for eight minutes. Second
dimension fractions were collected at 40 second intervals.
In solution trypsin digestion
The amount of protein from each fraction used for diges-
tion was determined based on peak UV absorbance at 214
nm. Samples were dried to 10 μL followed by addition of
50 mM ammonium bicarbonate and DTT. After 1 hr incu-
bation in a 60°C water bath, trypsin (0.125 mg/mL) was
added and samples incubated at 37°C for 14–16 hours.
Trypsinized samples were sonicated using a Branson water
bath sonicator for 5 seconds, a second volume of trypsin
added, and samples incubated at 37°C for 8–10 hours.
Formic acid was added to a final concentration of 0.1% to
stop the reaction. Peptides were purified using ZipTip®
(Millipore Corporation, Billerica, MA) according to man-
ufacturer's recommendation. Eluates were dried by vac-
uum centrifugation and resuspended in 12 μL of HPLC
water with 0.1% formic acid prior to mass spectrometer
analysis.
Protein identification by nano-LC-MS/MS
Peptides were fractionated on a RP-C18 microcapillary
column and sequenced using electrospray ionization-liq-
uid chromatography-mass spectrometry system (ESI-LC-
MS/MS) (ProteomeX system equipped with LCQDecaXP-
Plus mass spectrometer, ThermoElectron, Inc., San Jose,
CA) in a nanospray configuration. The mass accuracy of
the LCQDecaXPPlus is 500 ppm +/- 100 ppm. Database
nr.fasta was retrieved from the NCBI FTP server http://
www.ncbi.nlm.nih.gov/Ftp/ updated on April 11th, 2008.
The spectra obtained through LC-MS/MS analysis were
searched against the protein database narrowed to a sub-
set of human proteins (keywords: Homo sapiens, man,
human, primate) using SEQUEST algorithm (BioWorks
3.2 software from ThermoElectron, Inc.). We excluded
keratins from our database search based on previous
observations that these are contaminants resulting from
sample processing. In TurboSEQUEST Search Parameters,
threshold for Dta generation was 10000 and precursor
mass tolerance for Dta generation was set at 1.4. For Dta
Search, peptide tolerance was set at 1.5 and fragment ions
tolerance at 0.00. Charge state was set on "Auto." At least
two sequenced peptides were required from each protein
for high confidence identification.
SDS-PAGE
Selected second dimension protein fractions were
resolved further by electrophoresis through a NuPAGE®
Novex 4–12% Bis-Tris Gel (Invitrogen, Carlsbad, CA,
USA). Fractions were dried, resuspended in 20 μL of 1×
sample buffer with reducing agent (Invitrogen), and
heated at 95°C for 5 minutes. Electrophoresis was per-
formed at a constant 100 V for 90 min and the gel was
fixed in 40% methanol/7% acetic acid. After staining with
SYPRO® Ruby protein gel stain (Invitrogen), destaining
was achieved with 10% methanol/7% acetic acid and the
gel scanned using a Typhoon 9410 high performance laser
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scanning system (GE Healthcare/Amersham, Piscata, NJ).
Gels were subsequently counterstained with Coomassie
Brilliant Blue G-Colloidal (Sigma, St. Louis, MO) and
bands excised for in gel tryptic digestion.
In gel trypsin digestion
Gel pieces were distained for 1 hr at room temperature
using 100 μL of 50% acetonitrile/50 mM NH4HCO3. Gel
pieces were dried and incubated with trypsin in 10 mM
NH4HCO3 (Promega, Madison, WI) overnight at 37°C.
Peptides were extracted from trypsinized gels by washing
gel pieces for 2 hours with 0.1% TFA and 60% ACN and
were purified using ZipTip (Millipore Corporation). Zip-
Tip eluates were dried and resuspended in 12 μL of HPLC
water with 0.1% formic acid prior to mass spectrometer
analysis.
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